Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein
- 31 March 2010
- journal article
- Published by Elsevier BV in Journal of Biotechnology
- Vol. 146 (1-2), 84-91
- https://doi.org/10.1016/j.jbiotec.2010.01.011
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Genetic engineering of IgG-glucuronidase fusion proteinsJournal of Drug Targeting, 2009
- VEGF-Trap: A VEGF blocker with potent antitumor effectsProceedings of the National Academy of Sciences of the United States of America, 2002
- Expression of the neonatal Fc receptor (FcRn) at the blood–brain barrierJournal of Neurochemistry, 2002
- Mediated efflux of IgG molecules from brain to blood across the blood–brain barrierJournal of Neuroimmunology, 2001
- Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin ReceptorPharmaceutical Research, 2000
- Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate.Pharmaceutical Research, 1995
- Closed Head Injury Triggers Early Production of TNFα and IL-6 by Brain TissueJournal of Cerebral Blood Flow & Metabolism, 1994
- Physiological Parameters in Laboratory Animals and HumansPharmaceutical Research, 1993
- A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity.The Journal of Experimental Medicine, 1991
- Capillary Depletion Method for Quantification of Blood–Brain Barrier Transport of Circulating Peptides and Plasma ProteinsJournal of Neurochemistry, 1990